Royalty Pharma plc

NASDAQ:RPRX

32.77 (USD) • At close March 14, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 594564.69537.267567.978596536.313538.202683.971565.748573.463535.955562.049575.7585.773554.963573.027571539510.932500.879457.486464.277457.608434.883
Cost of Revenue 01.6546583.676.513277.137241.228118.8045.67305.061105.7145.67266.5055.7965.7335.671129.3415.7965.73388.012919.16122.33872.2150.033
Gross Profit 594563.036531.267-15.622519.487259.176296.974565.167560.078268.402430.241556.379309.195579.977549.23567.356441.659533.204505.199412.867-461.674341.939385.398384.85
Gross Profit Ratio 10.9970.989-0.0280.8720.4830.5520.8260.990.4680.8030.990.5370.990.990.990.7730.9890.9890.824-1.0090.7360.8420.885
Reseach & Development Expenses 10.50.50.5150.50.50.550.525.50.606100.5103.82190.53.1222.641855.7767.63915.8722.71821.45722.991
General & Administrative Expenses 6856.7254.70857.65259.18557.23447.63485.69573.22850.69251.84351.5446.16148.58844.92143.156505142.79938.06523.06125.60330.34924.426
Selling & Marketing Expenses 000.2920-0.1850000000000000000000
SG&A 6856.7254.70857.6525957.23447.63485.69573.22850.69251.84351.5446.16148.58844.92143.156505142.79938.06523.06125.60330.34924.426
Other Expenses 163-227.604-212.429-583.677-1.7071.091118.804308.848305.061105.714190.291-4.82-0.793-0.1070.043801310.261-5.9230.140.232-0.0370.058
Operating Expenses 232-170.384267.637641.752-17384.871289.362204.999432.576381.253158.163342.331422.283282.721-189.986343.7325828101.586139.449-874.433-68.221129.7493.983
Operating Income 362735.074269.63-73.774613151.442248.84478.97295.339192.21227.642219.718153.417303.052744.949229.297314511409.346361.431,331.919532.498327.859430.9
Operating Income Ratio 0.6091.3020.502-0.131.0290.2820.4620.70.1690.3350.4250.3910.2660.5171.3420.40.550.9480.8010.7222.9111.1470.7160.991
Total Other Income Expenses Net -2871.284-75.25369.501104.69-29.365102.49630.117-127.37528.204113.805-91.635-99.746-81.25661.806-70.31852.573113.687192.63-252.334114.609-92.471-149.089-34.806
Income Before Tax 334806.358194.377-4.273718122.077351.336509.089-610.03220.414491.597128.08353.671221.796806.755158.979367624601.976109.0961,446.528440.027178.77396.094
Income Before Tax Ratio 0.5621.4280.362-0.0081.2050.2280.6530.744-1.0780.3840.9170.2280.0930.3791.4540.2770.6431.1581.1780.2183.1620.9480.3910.911
Income Tax Expense 126092.373-9.05122349.963123.711168.3340.1392.582187.093167.95746.974119.867365.97989.86-531.38333.622159.90276.44378.81392.03188.04490.445
Net Income 208543.987102.0044.778494.3472.114227.625340.755-610.169217.832304.504-39.8747.904101.929440.77669.119171291442.07471.241,420.396408.982151.713367.444
Net Income Ratio 0.350.9630.190.0080.8290.1340.4230.498-1.0790.380.568-0.0710.0140.1740.7940.1210.2990.540.8650.1423.1050.8810.3320.845
EPS 0.461.610.230.0111.110.160.510.76-1.380.360.5-0.0660.0160.241.080.180.440.791.250.24.011.150.431.04
EPS Diluted 0.351.210.230.0111.110.160.50.76-1.380.360.5-0.0660.0110.241.080.110.440.791.250.24.011.150.431.04
EBITDA 362872.86456039.959673.865168.11398.285556.039-606.04267.391538.563225.38883.445308.848750.682234.968393.004516.363415.08367.1631,337.715538.294333.592437.499
EBITDA Ratio 0.6091.5460.502-0.131.0290.3130.5110.7710.2990.3350.7250.4160.2210.5521.410.4360.721.2260.8760.7092.9081.1520.7211.016